Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06919809 · ClinicalTrials.gov registry record · NA
Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery
A NA study of SCC - Squamous Cell Carcinoma and BCC - Basal Cell Carcinoma, sponsored by McGuire Institute.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06919809 is a NA study of SCC - Squamous Cell Carcinoma and BCC - Basal Cell Carcinoma that has completed, run by McGuire Institute. The registered enrollment target is 16 participants, below the 41-participant average among 4 other SCC - Squamous Cell Carcinoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06919809, a NA study of SCC - Squamous Cell Carcinoma and BCC - Basal Cell Carcinoma, has completed, sponsored by McGuire Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this single-arm clinical trial is to learn about the effectiveness and safety of the X A-DERM™ mADM in promoting wound healing and improving scar formation after MMS surgery for removing BCC, SCC, or MIS lesions on the face, head, and upper limbs. The main questions it aims to answer are how well this intervention works and what is the safety profile. The primary hypothesis is that the use of X A-DERM™ will result improved wound healing and scar formation after 60 days post-procedure. Participants will undergo MMS surgery to remove BCC, SCC, or MIS lesions, and then will receive the X A-DERM™ mADM graft at the surgical site. Participants will return to the office four additional times for the clinician to collect data on their wound healing. This will involve taking pictures of the wound, conducting clinical assessments (CROs), and documenting the patient's reported outcomes (PROs).
Conditions Studied
Interventions
- DEVICE A microsurfaced ADM (acellular dermal matrix)
Study Locations (1)
Texas
- Bare Dermatology - Rockwall
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-08-08 |
| Est. Completion | 2026-03-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06919809
The ClinicalTrials.gov registry entry for NCT06919809 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 4 other SCC - Squamous Cell Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is McGuire Institute, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with SCC - Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which A microsurfaced ADM (acellular dermal matrix) is the first listed.
NCT06919809 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06919809 about?
NCT06919809 is a clinical study titled "Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery". The goal of this single-arm clinical trial is to learn about the effectiveness and safety of the X A-DERM™ mADM in promoting wound healing and improving scar formation after MMS surgery for removing BCC, SCC, or MIS lesions on the face, head, and upper limbs. The main questions it aims to answer are...
What is the current status of trial NCT06919809?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2025-08-08. Estimated completion is 2026-03-06.
What conditions does trial NCT06919809 study?
This clinical trial studies the following conditions: SCC - Squamous Cell Carcinoma, BCC - Basal Cell Carcinoma, Wound Healing After MMS Surgery, Melanoma In Situ.
What interventions are being tested in trial NCT06919809?
The interventions under investigation include: A microsurfaced ADM (acellular dermal matrix) (DEVICE).
Who is sponsoring clinical trial NCT06919809?
This trial is sponsored by McGuire Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06919809 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SCC - Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High-Resolution PET-CT Imaging for Surgical Margin Visualization
RECRUITING · NA
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
RECRUITING · Early Phase 1
-
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.